Congress Asset Management Co. MA Increases Stake in Medpace Holdings, Inc
July 13, 2023
☀️Trending News
Medpace Holdings ($NASDAQ:MEDP), Inc is a clinical research organization and contract research organization (CRO) that provides customized services to the biopharmaceutical industry. It specializes in therapeutic areas such as oncology, cardiology, endocrinology, central nervous system, and infectious diseases. This additional support from investors serves to boost confidence in the company and provides a strong foundation for Medpace to continue to innovate and bring new products and services to market.
Market Price
On Friday, MEDPACE HOLDINGS stock opened at $233.9 and closed at $235.5, representing a 0.7% increase from the prior closing price of $234.0. Medpace Holdings is a clinical contract research organization engaged in providing drug development services to pharmaceutical and biotechnology companies as well as medical device manufacturers. The company provides a wide range of services including clinical project management, clinical monitoring, data management, laboratory services, clinical pharmacology, and regulatory consulting services. Medpace Holdings has offices in the United States, Europe, and Asia-Pacific and counts some of the world’s largest pharmaceutical and biotechnology companies among its clientele. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medpace Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.56k | 256.83 | 16.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medpace Holdings. More…
| Operations | Investing | Financing |
| 421.87 | -37.04 | -416.38 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.4k | 1.05k | 11.28 |
Key Ratios Snapshot
Some of the financial key ratios for Medpace Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.6% | 30.0% | 19.2% |
| FCF Margin | ROE | ROA |
| 24.6% | 51.2% | 13.5% |
Analysis
At GoodWhale, we offer comprehensive analysis of MEDPACE HOLDINGS‘s financials. Our Risk Rating indicates that MEDPACE HOLDINGS is a high risk investment. GoodWhale has detected two risk warnings in their income sheet, non financial. If you want to explore these warnings in more detail, make sure to register on goodwhale.com. Our platform will provide you with a comprehensive risk analysis of MEDPACE HOLDINGS’s financials. Additionally, you can take advantage of our advanced artificial intelligence algorithms to help you make informed decisions about your investments. With GoodWhale, you can be sure that you are making wise investments that will help you maximize your returns. More…
Peers
Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.
– Icon PLC ($NASDAQ:ICLR)
Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.
– Syneos Health Inc ($NASDAQ:SYNH)
Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.
Summary
Medpace Holdings, Inc. has recently gained the attention of investors, as Congress Asset Management Co. MA recently increased its stake in the company. A thorough analysis of the company is necessary to assess its growth potential and gain insights into its financial health. Analysts suggest looking at the company’s market capitalization and the multiples of its stock in order to compare it to its peers.
Additionally, analysts suggest assessing the company’s management team, financials, and customer base in order to evaluate its overall performance. Potential investors should also consider potential risks associated with investing in the company, such as market volatility or changes in competitive dynamics. Ultimately, investors should use a combination of technical and fundamental analysis to assess the company’s potential before committing their capital.
Related Posts
Recent Posts
